Apparently there will be no new research one way or the other emerging from this research crop come harvesting time.
Regardless, I think most here agree that Lipkin is putting together good research. That is not the issue.
The issue is, for some, the glaring omissions. They are hard to explain away, except for $'s, and cost is a very real consideration. Still, NO targeted evaluations at the role of prominent TBD's when you have prominent ME/CFS clinicians like Bell and KDM asserting their role? Aren't they worth at least, say, a token Western Blot to check for prior exposure? It doesn't even have to be 2T compliant - just a specific band or two...?
I feel like that little Dicken's waif asking for a bit more porridge, "Please, Sir..."
@barbc56 , you are right, of course, that not everything boils down to Lyme. You know I differentiate between ME/CFS and Lyme. We agree here. I just cannot get my brain around why he would decide not to take a look at TBD's given A) the similariities in presentations, B) the leading clinicians who think there is a tie, C) the extensive media coverage being generated about Lyme & Company recently, and D) the almost daily recalibrating of tick topography.
It seems to me this would have had to have been deliberate. It would be great if I could ask him. I suppose I can dredge up his email address somewhere; maybe I will.